Xeris Biopharma Holdings Inc (NASDAQ:XERS) has a beta value of 1.09 and has seen 6.35 million shares traded in the last trading session. The company, currently valued at $782.01M, closed the last trade at $5.08 per share which meant it lost -$0.41 on the day or -7.47% during that session. The XERS stock price is -19.49% off its 52-week high price of $6.07 and 66.73% above the 52-week low of $1.69. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.64 million shares traded. The 3-month trading volume is 2.62 million shares.
The consensus among analysts is that Xeris Biopharma Holdings Inc (XERS) is Buy stock at the moment, with a recommendation rating of 1.33. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.04.
Xeris Biopharma Holdings Inc (NASDAQ:XERS) trade information
Sporting -7.47% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the XERS stock price touched $5.08 or saw a rise of 16.31%. Year-to-date, Xeris Biopharma Holdings Inc shares have moved 49.85%, while the 5-day performance has seen it change -13.46%. Over the past 30 days, the shares of Xeris Biopharma Holdings Inc (NASDAQ:XERS) have changed 37.67%. Short interest in the company has seen 11.21 million shares shorted with days to cover at 3.4.
Wall Street analysts have a consensus price target for the stock at $5, which means that the shares’ value could drop -1.6% from current levels. The projected low price target is $4.0 while the price target rests at a high of $6.6. In that case, then, we find that the current price level is -29.92% off the targeted high while a plunge would see the stock lose 21.26% from current levels.
Xeris Biopharma Holdings Inc (XERS) estimates and forecasts
The company’s shares have gained 77.00% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 29.17%.
6 analysts offering their estimates for the company have set an average revenue estimate of 57.61M for the current quarter. 6 have an estimated revenue figure of 62.65M for the next ending quarter. Year-ago sales stood 40.64M and 48.06M respectively for this quarter and the next, and analysts expect sales will grow by 41.76% for the current quarter and 29.17% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 40.01% over the past 5 years.
XERS Dividends
Xeris Biopharma Holdings Inc is expected to release its next earnings report on 2025-Mar-05 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Xeris Biopharma Holdings Inc (NASDAQ:XERS)’s Major holders
Insiders own 3.97% of the company shares, while shares held by institutions stand at 42.81% with a share float percentage of 44.58%. Investors are also buoyed by the number of investors in a company, with Xeris Biopharma Holdings Inc having a total of 201.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 10.33 million shares worth more than $23.25 million. As of 2024-06-30, BLACKROCK INC. held 6.9649% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 7.66 million shares as of 2024-06-30. The firm’s total holdings are worth over $17.23 million and represent 5.4492% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . As of Dec 31, 2024 , the former fund manager holds about 2.74% shares in the company for having 4.22 shares of worth $21.44 million while later fund manager owns 3.58 shares of worth $18.2 million as of Feb 28, 2025 , which makes it owner of about 2.33% of company’s outstanding stock.
